Treatment of head and neck cancer with CHART and nimorazole: phase II study (Q33964073)

30 July 2017

Treatment of head and neck cancer with CHART and nimorazole: phase II study (English)

1 reference

30 July 2017

1 reference

1 reference

head and neck carcinoma

1 reference

J Michael Henk

1

1 reference

PubMed ID

12559522

30 July 2017

Kate Bishop

series ordinal

2

1 reference

PubMed ID

12559522

30 July 2017

Stephen F Shepherd

series ordinal

3

1 reference

30 July 2017

1 January 2003

1 reference

Radiotherapy and Oncology

30 July 2017

1 reference

30 July 2017

66

1 reference

30 July 2017

1

1 reference

30 July 2017

65-70

1 reference

Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Does hyperbaric oxygen have a future in radiation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Synchronous chemoradiation for squamous carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900284-0

7 January 2021

10.1016/S0167-8140(02)00284-0

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

12559522